No Cover Image

E-Thesis 222 views

Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine / ALICE LUTHER

Swansea University Author: ALICE LUTHER

  • Redacted version - open access under embargo until: 12th October 2025

DOI (Published version): 10.23889/SUthesis.58415

Abstract

Ovarian cancer (OC) is the 6th most common cancer in females and accounts for 5% of all female cancer deaths in the UK. OC presents with ambiguous symptoms often leading to a late diagnosis. Only 42.6% of women diagnosed with OC will survive for five years or more with many not responding to current...

Full description

Published: Swansea 2021
Institution: Swansea University
Degree level: Doctoral
Degree name: Ph.D
Supervisor: Gonzalez, Deyarina. ; Del Sol, Ricardo ; Conlan, Robert S.
URI: https://cronfa.swan.ac.uk/Record/cronfa58415
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2021-10-19T15:41:35Z
last_indexed 2021-10-27T03:23:53Z
id cronfa58415
recordtype RisThesis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2021-10-26T11:12:55.9267507</datestamp><bib-version>v2</bib-version><id>58415</id><entry>2021-10-19</entry><title>Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine</title><swanseaauthors><author><sid>cf8be1178dbcd57ed818f6702389d8df</sid><firstname>ALICE</firstname><surname>LUTHER</surname><name>ALICE LUTHER</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-10-19</date><abstract>Ovarian cancer (OC) is the 6th most common cancer in females and accounts for 5% of all female cancer deaths in the UK. OC presents with ambiguous symptoms often leading to a late diagnosis. Only 42.6% of women diagnosed with OC will survive for five years or more with many not responding to current treatments. Platinum-based drugs are the most widely used chemotherapy drugs in ovarian carcinoma, but their efficacy is not satisfactory. Bevacizumab and PARP inhibitors are the only targeted therapies currently approved for the treatment of this disease. Still, most patients will still recur and unfortunately succumb to this disease, thus new and more effective treatments and diagnosis methods are urgently needed. Antibody-Drug Conjugates (ADCs) are a group of targeted therapeutic molecules that have proved efficacious as therapeutic options for the treatment of various cancers such as Acute Myeloid Leukaemia and Hodgkin Lymphoma. Currently there is not an ADC approved for the treatment of ovarian cancer. ADCs couple the targeting activity of a monoclonal antibody with the cytotoxic activity of a potent small molecule drug to selectively destroy malignant cells while leaving the healthy cells unaffected. The discovery of novel ADC targets for the treatment of OC is crucial in combatting the poor prognosis associated with late-stage ovarian cancer. The late-stage diagnosis of OC is significantly associated with a reduced chance of survival. Confirmation of OC diagnosis is achieved through histological examination of biopsy tissue taken at surgery. This current diagnosis process is not appropriate for the high-throughput screening needed for the early detection of OC that could be offered if minimally invasive high-throughput liquid biopsy diagnostic tests are developed for OC. Objectives&#x2022;To identify and characterise transmembrane proteins as potential ADC targets&#x2022;To confirm the genetic stability of the antibody epitope DNA coding sequence in the Receptor for Advanced Glycation End products (RAGE) and the lead candidate ADC target&#x2022;To explore whether soluble RAGE (sRAGE) levels could serve as OC biomarker with diagnostic value using an Enzyme Linked Immunosorbent Assay (ELISA) liquid biopsy pipelineMethodology This study used western blots, immuno-fluorescent microscopy, internalisation assays by pH reactive dye, Illumina Next Generation Sequencing and Enzyme-Linked Immunosorbent assay. 2D cultured cells and protein were derived from primary patient biopsies. Eight immortalised ovarian cancer cell lines were used (See section 2.2.1.1). Results Immunofluorescent microscopy, immunoblotting and internalisation assay data in both ovarian cancer cell lines and cells derived from primary ovarian cancer patient biopsies revealed Tetraspanin 6 (TSPAN6) as the lead candidate target for novel ADC development. Not a lot is known about TSPAN6 function however it has been reported to mediate signal transduction events that play a role in the regulation of cell development, activation, growth, and motility. Three targets showed localisation to the cell membrane in ovarian cancer cells. Two targets (PCSK4 and TSPAN6), plus RAGE, showed antibody-internalisation capacity and translocation to the lysosomal compartment in cancer cells demonstrating their suitability as ADC targets. RAGE and TSPAN6 showed genetic stability by Illumina Next Generation Sequencing deep amplicon variant analysis. A novel TSPAN6 60 kDa immunoreactive protein band was identified in protein derived from a 3D primary tissue source and it significantly stratified OC from non-cancer patients. The ELISA technique was successful in detecting sRAGE in patient serum, however soluble serum RAGE levels did not exhibit a potential diagnostic value for OC disease in the clinical OC specimens analysed. Conclusions This thesis identified TSPAN6 as a novel ADC target for OC. In addition, both TSPAN6 and RAGE epitopes are highly conserved in humans, suggesting their promising therapeutic value for the development of immunotherapies. Nevertheless, levels of soluble serum RAGE are not indicators of an OC diagnosis.</abstract><type>E-Thesis</type><journal/><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher/><placeOfPublication>Swansea</placeOfPublication><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic/><keywords>ADC, novel targets, discovery pipeline, ovarian cancer, TSPAN6, precision medicine, western blot, immunofluorescent microscopy, ELISA, NGS</keywords><publishedDay>19</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-10-19</publishedDate><doi>10.23889/SUthesis.58415</doi><url/><notes>A selection of third party content is redacted or is partially redacted from this thesis due to copyright restrictions.</notes><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><supervisor>Gonzalez, Deyarina. ; Del Sol, Ricardo ; Conlan, Robert S.</supervisor><degreelevel>Doctoral</degreelevel><degreename>Ph.D</degreename><degreesponsorsfunders>NRN Life Sciences and Swansea University</degreesponsorsfunders><apcterm/><lastEdited>2021-10-26T11:12:55.9267507</lastEdited><Created>2021-10-19T16:31:22.1254146</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>ALICE</firstname><surname>LUTHER</surname><order>1</order></author></authors><documents><document><filename>Under embargo</filename><originalFilename>Under embargo</originalFilename><uploaded>2021-10-26T11:11:23.3116958</uploaded><type>Output</type><contentLength>53090075</contentLength><contentType>application/pdf</contentType><version>Redacted version - open access</version><cronfaStatus>true</cronfaStatus><embargoDate>2025-10-12T00:00:00.0000000</embargoDate><documentNotes>Copyright: The author, Alice Luther, 2021.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2021-10-26T11:12:55.9267507 v2 58415 2021-10-19 Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine cf8be1178dbcd57ed818f6702389d8df ALICE LUTHER ALICE LUTHER true false 2021-10-19 Ovarian cancer (OC) is the 6th most common cancer in females and accounts for 5% of all female cancer deaths in the UK. OC presents with ambiguous symptoms often leading to a late diagnosis. Only 42.6% of women diagnosed with OC will survive for five years or more with many not responding to current treatments. Platinum-based drugs are the most widely used chemotherapy drugs in ovarian carcinoma, but their efficacy is not satisfactory. Bevacizumab and PARP inhibitors are the only targeted therapies currently approved for the treatment of this disease. Still, most patients will still recur and unfortunately succumb to this disease, thus new and more effective treatments and diagnosis methods are urgently needed. Antibody-Drug Conjugates (ADCs) are a group of targeted therapeutic molecules that have proved efficacious as therapeutic options for the treatment of various cancers such as Acute Myeloid Leukaemia and Hodgkin Lymphoma. Currently there is not an ADC approved for the treatment of ovarian cancer. ADCs couple the targeting activity of a monoclonal antibody with the cytotoxic activity of a potent small molecule drug to selectively destroy malignant cells while leaving the healthy cells unaffected. The discovery of novel ADC targets for the treatment of OC is crucial in combatting the poor prognosis associated with late-stage ovarian cancer. The late-stage diagnosis of OC is significantly associated with a reduced chance of survival. Confirmation of OC diagnosis is achieved through histological examination of biopsy tissue taken at surgery. This current diagnosis process is not appropriate for the high-throughput screening needed for the early detection of OC that could be offered if minimally invasive high-throughput liquid biopsy diagnostic tests are developed for OC. Objectives•To identify and characterise transmembrane proteins as potential ADC targets•To confirm the genetic stability of the antibody epitope DNA coding sequence in the Receptor for Advanced Glycation End products (RAGE) and the lead candidate ADC target•To explore whether soluble RAGE (sRAGE) levels could serve as OC biomarker with diagnostic value using an Enzyme Linked Immunosorbent Assay (ELISA) liquid biopsy pipelineMethodology This study used western blots, immuno-fluorescent microscopy, internalisation assays by pH reactive dye, Illumina Next Generation Sequencing and Enzyme-Linked Immunosorbent assay. 2D cultured cells and protein were derived from primary patient biopsies. Eight immortalised ovarian cancer cell lines were used (See section 2.2.1.1). Results Immunofluorescent microscopy, immunoblotting and internalisation assay data in both ovarian cancer cell lines and cells derived from primary ovarian cancer patient biopsies revealed Tetraspanin 6 (TSPAN6) as the lead candidate target for novel ADC development. Not a lot is known about TSPAN6 function however it has been reported to mediate signal transduction events that play a role in the regulation of cell development, activation, growth, and motility. Three targets showed localisation to the cell membrane in ovarian cancer cells. Two targets (PCSK4 and TSPAN6), plus RAGE, showed antibody-internalisation capacity and translocation to the lysosomal compartment in cancer cells demonstrating their suitability as ADC targets. RAGE and TSPAN6 showed genetic stability by Illumina Next Generation Sequencing deep amplicon variant analysis. A novel TSPAN6 60 kDa immunoreactive protein band was identified in protein derived from a 3D primary tissue source and it significantly stratified OC from non-cancer patients. The ELISA technique was successful in detecting sRAGE in patient serum, however soluble serum RAGE levels did not exhibit a potential diagnostic value for OC disease in the clinical OC specimens analysed. Conclusions This thesis identified TSPAN6 as a novel ADC target for OC. In addition, both TSPAN6 and RAGE epitopes are highly conserved in humans, suggesting their promising therapeutic value for the development of immunotherapies. Nevertheless, levels of soluble serum RAGE are not indicators of an OC diagnosis. E-Thesis Swansea ADC, novel targets, discovery pipeline, ovarian cancer, TSPAN6, precision medicine, western blot, immunofluorescent microscopy, ELISA, NGS 19 10 2021 2021-10-19 10.23889/SUthesis.58415 A selection of third party content is redacted or is partially redacted from this thesis due to copyright restrictions. COLLEGE NANME COLLEGE CODE Swansea University Gonzalez, Deyarina. ; Del Sol, Ricardo ; Conlan, Robert S. Doctoral Ph.D NRN Life Sciences and Swansea University 2021-10-26T11:12:55.9267507 2021-10-19T16:31:22.1254146 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine ALICE LUTHER 1 Under embargo Under embargo 2021-10-26T11:11:23.3116958 Output 53090075 application/pdf Redacted version - open access true 2025-10-12T00:00:00.0000000 Copyright: The author, Alice Luther, 2021. true eng
title Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine
spellingShingle Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine
ALICE LUTHER
title_short Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine
title_full Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine
title_fullStr Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine
title_full_unstemmed Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine
title_sort Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and precision medicine
author_id_str_mv cf8be1178dbcd57ed818f6702389d8df
author_id_fullname_str_mv cf8be1178dbcd57ed818f6702389d8df_***_ALICE LUTHER
author ALICE LUTHER
author2 ALICE LUTHER
format E-Thesis
publishDate 2021
institution Swansea University
doi_str_mv 10.23889/SUthesis.58415
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
description Ovarian cancer (OC) is the 6th most common cancer in females and accounts for 5% of all female cancer deaths in the UK. OC presents with ambiguous symptoms often leading to a late diagnosis. Only 42.6% of women diagnosed with OC will survive for five years or more with many not responding to current treatments. Platinum-based drugs are the most widely used chemotherapy drugs in ovarian carcinoma, but their efficacy is not satisfactory. Bevacizumab and PARP inhibitors are the only targeted therapies currently approved for the treatment of this disease. Still, most patients will still recur and unfortunately succumb to this disease, thus new and more effective treatments and diagnosis methods are urgently needed. Antibody-Drug Conjugates (ADCs) are a group of targeted therapeutic molecules that have proved efficacious as therapeutic options for the treatment of various cancers such as Acute Myeloid Leukaemia and Hodgkin Lymphoma. Currently there is not an ADC approved for the treatment of ovarian cancer. ADCs couple the targeting activity of a monoclonal antibody with the cytotoxic activity of a potent small molecule drug to selectively destroy malignant cells while leaving the healthy cells unaffected. The discovery of novel ADC targets for the treatment of OC is crucial in combatting the poor prognosis associated with late-stage ovarian cancer. The late-stage diagnosis of OC is significantly associated with a reduced chance of survival. Confirmation of OC diagnosis is achieved through histological examination of biopsy tissue taken at surgery. This current diagnosis process is not appropriate for the high-throughput screening needed for the early detection of OC that could be offered if minimally invasive high-throughput liquid biopsy diagnostic tests are developed for OC. Objectives•To identify and characterise transmembrane proteins as potential ADC targets•To confirm the genetic stability of the antibody epitope DNA coding sequence in the Receptor for Advanced Glycation End products (RAGE) and the lead candidate ADC target•To explore whether soluble RAGE (sRAGE) levels could serve as OC biomarker with diagnostic value using an Enzyme Linked Immunosorbent Assay (ELISA) liquid biopsy pipelineMethodology This study used western blots, immuno-fluorescent microscopy, internalisation assays by pH reactive dye, Illumina Next Generation Sequencing and Enzyme-Linked Immunosorbent assay. 2D cultured cells and protein were derived from primary patient biopsies. Eight immortalised ovarian cancer cell lines were used (See section 2.2.1.1). Results Immunofluorescent microscopy, immunoblotting and internalisation assay data in both ovarian cancer cell lines and cells derived from primary ovarian cancer patient biopsies revealed Tetraspanin 6 (TSPAN6) as the lead candidate target for novel ADC development. Not a lot is known about TSPAN6 function however it has been reported to mediate signal transduction events that play a role in the regulation of cell development, activation, growth, and motility. Three targets showed localisation to the cell membrane in ovarian cancer cells. Two targets (PCSK4 and TSPAN6), plus RAGE, showed antibody-internalisation capacity and translocation to the lysosomal compartment in cancer cells demonstrating their suitability as ADC targets. RAGE and TSPAN6 showed genetic stability by Illumina Next Generation Sequencing deep amplicon variant analysis. A novel TSPAN6 60 kDa immunoreactive protein band was identified in protein derived from a 3D primary tissue source and it significantly stratified OC from non-cancer patients. The ELISA technique was successful in detecting sRAGE in patient serum, however soluble serum RAGE levels did not exhibit a potential diagnostic value for OC disease in the clinical OC specimens analysed. Conclusions This thesis identified TSPAN6 as a novel ADC target for OC. In addition, both TSPAN6 and RAGE epitopes are highly conserved in humans, suggesting their promising therapeutic value for the development of immunotherapies. Nevertheless, levels of soluble serum RAGE are not indicators of an OC diagnosis.
published_date 2021-10-19T04:14:55Z
_version_ 1763754005925724160
score 11.013148

Similar Items